Using molecular oxygen and Fe-N/C heterogeneous catalysts to achieve Mukaiyama epoxidations via in situ produced organic peroxy acids and acylperoxy radicals

Under mild conditions of room temperature and pressure, and using either pure oxygen or air, aldehydes are converted using a heterogeneous Fe–N/C catalyst to produce the corresponding organic peroxy acid and acylperoxy radicals, which forms the epoxide from cyclohexene with high yield (91% for isobutyraldehyde in O2). Real-time monitoring of the rate of oxygen consumption and the electrochemical potential of the Fe–N/C catalyst has been used to study the formation of the peroxy acid and subsequent catalytic epoxidation of cyclohexene. Using isobutyraldehyde, it is shown that the aldehyde and the iron-based carbon catalyst (Fe–N/C) are involved in the rate determining step. Addition of a radical scavenger increases the induction time showing that radicals are initiated by the reaction between the aldehyde and the catalyst. Furthermore, UV-vis spectroscopy with 2,2′-azino-di-(3-ethylbenzthiazoline sulfonic acid) (ABTS) proved the in situ formation of peroxy acid. In the presence of cyclohexene, the peroxy acid leads to the corresponding epoxide with high yield. Monitoring the open circuit potential (OCP) and oxygen flow concurrently follows the production of the peroxy acid. The epoxidation reaction can take place only when the increase in open circuit potential is greater than 0.14 V, suggesting an in situ direct link between the relative oxidative strength of the peroxy acid and the likelihood of epoxidation

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

BACKGROUND: T-cell infiltration in estrogen receptor (ER)-negative breast tumours has been associated with longer survival. To investigate this association and the potential of tumour T-cell infiltration as a prognostic and predictive marker, we have conducted the largest study of T cells in breast cancer to date. PATIENTS AND METHODS: Four studies totalling 12 439 patients were used for this work. Cytotoxic (CD8+) and regulatory (forkhead box protein 3, FOXP3+) T cells were quantified using immunohistochemistry (IHC). IHC for CD8 was conducted using available material from all four studies (8978 samples) and for FOXP3 from three studies (5239 samples)-multiple imputation was used to resolve missing data from the remaining patients. Cox regression was used to test for associations with breast cancer-specific survival. RESULTS: In ER-negative tumours [triple-negative breast cancer and human epidermal growth factor receptor 2 (human epidermal growth factor receptor 2 (HER2) positive)], presence of CD8+ T cells within the tumour was associated with a 28% [95% confidence interval (CI) 16% to 38%] reduction in the hazard of breast cancer-specific mortality, and CD8+ T cells within the stroma with a 21% (95% CI 7% to 33%) reduction in hazard. In ER-positive HER2-positive tumours, CD8+ T cells within the tumour were associated with a 27% (95% CI 4% to 44%) reduction in hazard. In ER-negative disease, there was evidence for greater benefit from anthracyclines in the National Epirubicin Adjuvant Trial in patients with CD8+ tumours [hazard ratio (HR) = 0.54; 95% CI 0.37-0.79] versus CD8-negative tumours (HR = 0.87; 95% CI 0.55-1.38). The difference in effect between these subgroups was significant when limited to cases with complete data (P heterogeneity = 0.04) and approached significance in imputed data (P heterogeneity = 0.1). CONCLUSIONS: The presence of CD8+ T cells in breast cancer is associated with a significant reduction in the relative risk of death from disease in both the ER-negative [supplementary Figure S1, available at Annals of Oncology online] and the ER-positive HER2-positive subtypes. Tumour lymphocytic infiltration may improve risk stratification in breast cancer patients classified into these subtypes. NEAT ClinicalTrials.gov: NCT00003577.This work was supported by Cancer Research UK (C490/A10119 and C490/A10124) and the NIHR Cambridge Biomedical Research Centre. HRA was supported by a grant from Addenbrooke’s Charitable Trust. The BCCA study was supported by an unrestricted educational grant from Sanofi-Aventis Canada. SMAM was supported by a PhD studentship funded by the Government of Egypt. IOE was funded by Breast Cancer Campaign.This is the author accepted manuscript. The final version can be found on the publisher's website at: http://annonc.oxfordjournals.org/content/early/2014/06/09/annonc.mdu191.long © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved

A quick and versatile one step metal–organic chemical deposition method for supported Pt and Pt-alloy catalysts

A simple, modified Metal–Organic Chemical Deposition (MOCD) method for Pt, PtRu and PtCo nanoparticle deposition onto a variety of support materials, including C, SiC, B4C, LaB6, TiB2, TiN and a ceramic/carbon nanofiber, is described. Pt deposition using Pt(acac)2 as a precursor is shown to occur via a mixed solid/liquid/vapour precursor phase which results in a high Pt yield of 90–92% on the support material. Pt and Pt alloy nanoparticles range 1.5–6.2 nm, and are well dispersed on all support materials, in a one-step method, with a total catalyst preparation time of ∼10 hours (2.4–4× quicker than conventional methods). The MOCD preparation method includes moderate temperatures of 350 °C in a tubular furnace with an inert gas supply at 2 bar, a high pressure (2–4 bar) compared to typical MOCVD methods (∼0.02–10 mbar). Pt/C catalysts with Pt loadings of 20, 40 and 60 wt% were synthesised, physically characterised, electrochemically characterised and compared to commercial Pt/C catalysts. TEM, XRD and ex situ EXAFS show similar Pt particle sizes and Pt particle shape identifiers, namely the ratio of the third to first Pt coordination numbers modelled from ex situ EXAFS, between the MOCD prepared catalysts and commercial catalysts. Moreover, electrochemical characterisation of the Pt/C MOCD catalysts obtained ORR mass activities with a maximum of 428 A gPt−1 at 0.9 V, which has similar mass activities to the commercial catalysts (80–160% compared to the commercial Pt/C catalysts)

Parsonage-Turner Syndrome

Parsonage-Turner Syndrome (PTS), also referred to as idiopathic brachial plexopathy or neuralgic amyotrophy, is a rare disorder consisting of a complex constellation of symptoms with abrupt onset of shoulder pain, usually unilaterally, followed by progressive neurologic deficits of motor weakness, dysesthesias, and numbness. Although the etiology of the syndrome is unclear, it is reported in various clinical situations, including postoperatively, postinfectious, posttraumatic, and postvaccination. The identification of the syndrome in the postoperative patient remains a challenge as symptoms may easily be attributed to sequelae of surgical positioning, postoperative recovery, or postanesthetic block pain. The purpose of this review is to bring forth salient, identifiable factors which may assist the surgical clinician in identifying the condition sooner. An early and proper diagnosis affords the opportunity to treat the patient accordingly and to the satisfaction of both surgeon and patient